MedPath

A comparative evaluation of two different approaches for lumbar transforaminal epidural injection in patients with lumbar radiculopathy

Completed
Conditions
Nerve root and plexus disorder, unspecified,
Registration Number
CTRI/2021/01/030167
Brief Summary

·        Lumbar radiculopathy affectssignificant number of patients causing severe neurogenic pain. Transforaminalepidural injection of local anaesthetic and steroid is an effective treatmentfor this condition. Subpedicular approach is usually used for transforaminalepidural injection but has the risk of nerve and vessel injury. Kambin describedthe kambin’s triangle, approach through which can lead to less chance of neurovascularinjury. Aim of our study is to compare these two approaches and anycomplication during procedure and post procedure pain relief and anycomplication .

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Lumbar radiculopathy 2.
  • ASA I, II, III 3.
  • Scheduled for transforaminal epidural injection.
Exclusion Criteria

Severe uncontrolled diabetes mellitus, hypertension Patients on steroid Coagulopathy Previous knee exploration • ASA IV.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
TO COMPARE THE FLUOROSCOPY GUIDED SUBPEDICULAR APPROACH AND THE APPROACH USING KAMBINS TRIANGLE IN TRANSFORAMINAL EPIDURAL INJECTION PERFORMED IN PATIENTS WITH SPINAL STENOSIS COMPLAINING OF LUMBAR RADICULAR PAIN in terms of pain relief and functional improvement1st January, 2021 to 30th June, 2021
Secondary Outcome Measures
NameTimeMethod
to investigate and compare the intra procedure complications and post procedure side effects for both the approach.01.01.2020 to 30.06.2020

Trial Locations

Locations (1)

RG Kar MCH

🇮🇳

Kolkata, WEST BENGAL, India

RG Kar MCH
🇮🇳Kolkata, WEST BENGAL, India
Dr Rajasree Biswas
Principal investigator
9433875954
docrajasree@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.